Comparative risk of reactivation of hepatitis B and C after treatment with biologics and targeted synthetic disease-modifying antirheumatic drugs in psoriasis and psoriatic arthritis: A 15-year multicenter cohort study
Comparative risk of reactivation of hepatitis B and C after treatment with biologics and targeted synthetic disease-modifying antirheumatic drugs in psoriasis and psoriatic arthritis: A 15-year multicenter cohort study. // Journal of the American Academy of Dermatology. – URL: https://www.sciencedirect.com/science/article/pii/S0190962226030343?dgcid=rss_sd_all
Comparative risk of reactivation of hepatitis B and C after treatment with biologics and targeted synthetic disease-modifying antirheumatic drugs in psoriasis and psoriatic arthritis: A 15-year multicenter cohort study. Journal of the American Academy of Dermatology. https://www.sciencedirect.com/science/article/pii/S0190962226030343?dgcid=rss_sd_all
“Comparative risk of reactivation of hepatitis B and C after treatment with biologics and targeted synthetic disease-modifying antirheumatic drugs in psoriasis and psoriatic arthritis: A 15-year multicenter cohort study.” Journal of the American Academy of Dermatology.
@article{article89953,
title = {Comparative risk of reactivation of hepatitis B and C after treatment with biologics and targeted synthetic disease-modifying antirheumatic drugs in psoriasis and psoriatic arthritis: A 15-year multicenter cohort study},
journal = {Journal of the American Academy of Dermatology},
url = {https://www.sciencedirect.com/science/article/pii/S0190962226030343?dgcid=rss_sd_all}
}